ES2608956T3 - Método, serie y uso de los mismos - Google Patents

Método, serie y uso de los mismos Download PDF

Info

Publication number
ES2608956T3
ES2608956T3 ES11736127.9T ES11736127T ES2608956T3 ES 2608956 T3 ES2608956 T3 ES 2608956T3 ES 11736127 T ES11736127 T ES 11736127T ES 2608956 T3 ES2608956 T3 ES 2608956T3
Authority
ES
Spain
Prior art keywords
proteome
sample
subject
additional
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11736127.9T
Other languages
English (en)
Spanish (es)
Inventor
Carl Arne Krister Borrebaeck
Christer Lars Bertil Wingren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovia AB
Original Assignee
Immunovia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia AB filed Critical Immunovia AB
Application granted granted Critical
Publication of ES2608956T3 publication Critical patent/ES2608956T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES11736127.9T 2010-06-11 2011-06-09 Método, serie y uso de los mismos Active ES2608956T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201009798 2010-06-11
GBGB1009798.8A GB201009798D0 (en) 2010-06-11 2010-06-11 Method,array and use thereof
PCT/GB2011/000865 WO2011154698A2 (en) 2010-06-11 2011-06-09 Method,array and use thereof

Publications (1)

Publication Number Publication Date
ES2608956T3 true ES2608956T3 (es) 2017-04-17

Family

ID=42471508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11736127.9T Active ES2608956T3 (es) 2010-06-11 2011-06-09 Método, serie y uso de los mismos

Country Status (11)

Country Link
US (2) US20130143760A1 (https=)
EP (1) EP2580592B1 (https=)
JP (1) JP6104796B2 (https=)
CN (1) CN103038642B (https=)
AU (1) AU2011263533B2 (https=)
BR (1) BR112012031444A2 (https=)
CA (1) CA2801863A1 (https=)
ES (1) ES2608956T3 (https=)
GB (1) GB201009798D0 (https=)
IN (1) IN2013CN00297A (https=)
WO (1) WO2011154698A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
AU2015263998A1 (en) * 2014-05-22 2016-12-08 Northwestern University Gene expression profiles associated with sub-clinical kidney transplant rejection
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
BR112017007962A2 (pt) * 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
CA2976947C (en) * 2015-02-18 2023-02-28 Siemens Healthcare Diagnostics Inc. Locality-based detection of tray slot types and tube types in a vision system
TWI582240B (zh) * 2015-05-19 2017-05-11 鄭鴻鈞 以基因體預後評估試劑組預測乳癌患者局部區域復發風險及放射治療有效性的方法、用途及裝置
WO2017096405A1 (en) * 2015-12-04 2017-06-08 Nx Prenatal Inc. Use of circulating microparticles to stratify risk of spontaneous preterm birth
CN109444402B (zh) * 2018-12-18 2021-05-28 郑州安图生物工程股份有限公司 去甲肾上腺素发光免疫检测试剂盒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12586T1 (de) 1980-05-02 1985-04-15 Edward P Davis Beinentlastungsgeraet.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5376531A (en) 1992-09-03 1994-12-27 Northwestern University Method of detecting cancer
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
EP1876241A3 (en) 1996-01-11 2008-07-30 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
RO114835B1 (ro) 1997-03-17 1999-07-30 Ioan Puşcaş Metodă rapidă de diagnostic al cancerelor
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US6492505B1 (en) 1999-02-01 2002-12-10 Incyte Genomics, Inc. Composition for detection of genes encoding membrane-associated proteins
WO2002101357A2 (en) 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
AU2003284880A1 (en) 2002-10-24 2004-05-13 Duke University Evaluation of breast cancer states and outcomes using gene expression profiles
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040259161A1 (en) 2003-03-12 2004-12-23 Fredrik Nilsson Screening assay
WO2004106495A2 (en) 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
JP4443568B2 (ja) 2003-10-15 2010-03-31 エフ．ホフマン−ラ ロシュ アーゲー 乳癌に対するマーカーとしてのタンパク質ａｓｃの使用
WO2005080570A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Rayon Co., Ltd. 乳癌の術後予後予測に関与する遺伝子
US20090166224A1 (en) 2004-05-05 2009-07-02 Ziping Yang Multi-lectin affinity chromatography and uses thereof
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
WO2007002069A2 (en) 2005-06-21 2007-01-04 Anthony Goncalves Serum biomarkers for breast cancer
US7972770B2 (en) 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20080311601A1 (en) 2005-11-02 2008-12-18 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
US9095549B2 (en) * 2005-12-16 2015-08-04 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
SG142186A1 (en) 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
GB0723179D0 (en) 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
US20090239229A1 (en) * 2008-03-14 2009-09-24 Dnar, Inc DNA Repair Proteins Associated With Triple Negative Breast Cancers and Methods of Use Thereof
EP2105740A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Biomarkers for monitoring or predicting the treatment of cancer
EP2281063B1 (en) 2008-04-29 2014-10-15 Siemens Healthcare Diagnostics GmbH A method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment
JP2010151800A (ja) 2008-11-06 2010-07-08 Kumamoto Univ 生活習慣病及び／又は癌の診断剤
WO2010076322A1 (en) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
EP2391962B1 (en) 2009-01-28 2016-12-21 University of Notre Dame du Lac Accelerated progression relapse test
MX337650B (es) 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
GB201410226D0 (en) 2014-06-09 2014-07-23 Immunovia Ab Methods and arrays for use in the same

Also Published As

Publication number Publication date
CN103038642A (zh) 2013-04-10
EP2580592A2 (en) 2013-04-17
WO2011154698A8 (en) 2013-01-17
BR112012031444A2 (pt) 2016-10-25
AU2011263533B2 (en) 2016-11-03
US10564163B2 (en) 2020-02-18
AU2011263533A8 (en) 2013-03-21
AU2011263533A1 (en) 2013-01-10
EP2580592B1 (en) 2016-10-05
US20180313852A1 (en) 2018-11-01
IN2013CN00297A (https=) 2015-07-03
WO2011154698A2 (en) 2011-12-15
JP2013529773A (ja) 2013-07-22
CN103038642B (zh) 2017-02-22
CA2801863A1 (en) 2011-12-15
WO2011154698A3 (en) 2012-03-01
JP6104796B2 (ja) 2017-03-29
US20130143760A1 (en) 2013-06-06
GB201009798D0 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
ES2608956T3 (es) Método, serie y uso de los mismos
Li et al. Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
Eggermont et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity
Soll et al. Expression of serotonin receptors in human hepatocellular cancer
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
Bidard et al. Time‐dependent prognostic impact of circulating tumor cells detection in non‐metastatic breast cancer: 70‐month analysis of the REMAGUS02 study
CY1120087T1 (el) Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους
ES2720999T3 (es) Método y sistema para seleccionar un fármaco sobre la base de la información del daño de proteína individual para prevenir los efectos secundarios de un fármaco
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
JP2014144959A5 (https=)
JP2013529773A5 (https=)
Wang et al. Prognostic role of SPARC expression in gastric cancer: a meta-analysis
Gao et al. Clinical roles of miR-136-5p and its target metadherin in thyroid carcinoma
Tong et al. Emodin reverses gemcitabine resistance of pancreatic cancer cell lines through inhibition of IKKβ/NF-κB signaling pathway
BR112015010399A2 (pt) método e kit para a determinação de cobre livre no soro
BR112015019567A8 (pt) inibidor de wnt, seu uso e métodos para prognosticar sensibilidade ao mesmo, e composição farmacêutica
Rowe et al. TroVax in colorectal cancer
Liu et al. Nuclear survivin promoted by acetylation is associated with the aggressive phenotype of oral squamous cell carcinoma
Stoetzer et al. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy
Yang et al. RETRACTED ARTICLE: The Clinical Utility of Matrix Metalloproteinase 9 in Evaluating Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis
Kadletz et al. Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas
Chen et al. Replication Factor C4 in human hepatocellular carcinoma: A potent prognostic factor associated with cell proliferation
MX2015001788A (es) Metabolitos de metionina predicen la evolución agresiva del cáncer.
Kassahun Controversies in defining prognostic relevant selection criteria that determine long-term effectiveness of liver resection for noncolorectal nonneuroendocrine liver metastasis